Format

Send to

Choose Destination
See comment in PubMed Commons below
Arq Bras Endocrinol Metabol. 2010 Mar;54(2):200-5.

SERMs in the prevention and treatment of postmenopausal osteoporosis: an update.

Author information

1
Hospital de Clínicas, Universidade Federal do Paraná, Curitiba, PR, Brasil. jkulak@ufpr.br <jkulak@ufpr.br>

Abstract

Selective estrogen receptor modulators (SERMs) have the ability to bind the estrogen receptor (ER) and are known to confer ER agonist or antagonist effects depending on the target tissue. A number of newer SERMs, including bazedoxifene, lasofoxifene and ospemifene, are currently under clinical development for the prevention and treatment of postmenopausal osteoporosis and for other indications. Although the possibility of developing a single agent that has all of the desired characteristics of an ideal SERM seems to be unlikely, progress in the clinical development of SERMs targeted to the ER suggests that these newer compounds may have attributes that represent an improvement relative to existing SERMs. A new approach to menopausal therapy is the tissue selective estrogen complex or the pairing of a selective estrogen receptor modulator with estrogens. Further investigation will help to clarify relative benefits/risks of novel SERMs in development within specific indications.

PMID:
20485909
PMCID:
PMC3109295
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Scientific Electronic Library Online Icon for PubMed Central
    Loading ...
    Support Center